Keywords: Seattle Genetics, GlaxoSmithKline, ADC technoilogy, chemotherapy, Licensing, Monoclonal antibodies

Seattle Genetics in deal with GSK for ADC worth up to $402 million

Article | 22 December 2009

Print This

US biotechnology firm Seattle Genetics has secured an initial $12 million from UK drug giant GlaxoSmithKline under which GSK will acquire ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in